The IP Questions That End University Spinout Meetings

The pitch went well. The science landed, the market slide held up, and the Q&A has been friendly. Then someone near the end of the table asks a quiet, reasonable question:

"Who actually owns the technology?"

And the founder says some version of:

"The university does, but we have a license. The tech transfer office handles the details."

The temperature in the room changes. Nobody says anything unkind. But a meeting that was heading toward diligence is now heading toward "let's stay in touch."

When we wrote about why your SBIR narrative isn't a pitch deck, we promised a follow-up on this question, because in our experience it ends more spinout meetings than almost any slide in the deck. Here it is.

---

Why Investors Care So Much

In most startups, intellectual property is simple. Employees write the code under an assignment agreement, and the company owns what they build.

A university spinout is different. Its core technology almost always started life inside the university, often funded by federal grants. The university owns it. The company holds a license — a contract granting rights to use it, on terms, with conditions.

That means an investor isn't evaluating an asset the company owns outright. They're evaluating a contract, and the contract determines what they're actually buying. If the terms are unclear, they may be buying a future dispute along with the company.

So the question isn't a formality. It's diligence, starting early.

---

The Five Questions to Answer Cold

1. Who holds the patents, and what's their status?

Almost always the university. Know which patents and applications you're licensing, whether each is issued or pending, what they cover, and where they're filed. "We have some patents" is not an answer. "Two issued U.S. patents and one pending PCT application, covering the core method and the device" is.

2. What does the license actually say?

Many founders haven't read their own license closely, and this is where it shows. The terms that matter most:

• Exclusive or non-exclusive. Non-exclusive rights to your core technology means a competitor could license the same thing. That changes the whole investment case.
• Field of use. Licenses are often limited to specific applications. If your beachhead market sits outside the licensed field — or your likely pivot does — you have a problem nobody has noticed yet.
• Territory. U.S. only, or worldwide?
• Diligence milestones. Many licenses require you to hit development or commercial milestones on a schedule, or risk losing exclusivity. Know them, and know whether your plan actually hits them.
• Sublicensing and assignment. Can you sublicense to partners? Can the license transfer if the company is acquired? An acquirer buying a company whose key license can't move with it is buying far less than it thinks — and the exit is how the investment pays off.

3. What does the university get?

Equity, royalties on sales, milestone payments, reimbursement of patent costs, or some combination. Investors will want to model all of it.

Pay particular attention to equity terms. Some university agreements include anti-dilution protection that keeps the institution's stake from shrinking until a certain amount has been raised. That directly affects what new investors can own, and it will surface in diligence whether or not you mention it.

4. What rights did the government keep?

If federal grants funded the research — SBIR, NIH, NSF, DoD — the Bayh-Dole Act attaches conditions to the invention:

• A government license. The federal government keeps a non-exclusive, royalty-free right to use the invention for government purposes.
• A U.S. manufacturing preference. An exclusive licensee generally has to manufacture products for U.S. sale substantially in the United States, unless a waiver is granted. For hardware and life science spinouts planning to manufacture overseas, this matters a great deal.
• March-in rights. In certain circumstances, the funding agency can require the rights to be licensed to others — most notably if the invention isn't being developed toward practical use.
• Disclosure and title obligations. The university had to report the invention and elect to keep title within set deadlines. If it didn't, the government's claim to the invention gets stronger.

For decades, march-in rights were treated as theoretical. They had never been exercised. That began to change in August 2025, when the Commerce Department opened a review of Harvard's federally funded patents — the first time the government initiated a march-in proceeding itself rather than responding to a petition. The grounds it cited were late disclosure, the manufacturing preference, and failure to commercialize. Separately, draft guidance that would let agencies weigh price in march-in decisions remains unfinalized.

Whatever happens in any single case, the practical effect is that more investors now ask about Bayh-Dole compliance as a real diligence item. The university's paperwork has become your risk.

5. Who else is on the invention?

Graduate students, postdocs, other faculty, collaborators at other institutions. If a co-inventor sits at a second university, you may need a second license, or an inter-institutional agreement governing the first.

Faculty founders bring their own questions. University conflict-of-interest policies often limit outside time commitments and decision-making roles. Can your faculty co-founder actually be full-time, or serve as an officer? And what happens to improvements their lab makes after the license is signed — does your license cover future lab work, or will each improvement need a new negotiation?

---

What "Clean" Looks Like

A spinout whose IP answer survives diligence usually has:

• An exclusive license in a field of use that comfortably covers both the beachhead and the most likely adjacent markets
• Milestones the operating plan actually hits, with some margin
• A license that can transfer on acquisition, or a clear consent process for one
• University economics sized sensibly for the stage, with any anti-dilution terms understood and disclosed
• Bayh-Dole compliance documented — disclosure dates, title election, any waivers
• Every inventor identified, with assignments to the university in order

None of that is unusual, and most of it is achievable. The founder just has to know where the company stands on each one.

---

What to Do Before You Pitch

Read your license yourself. All of it. Not the term sheet, not the summary from the tech transfer office — the executed agreement.

Write a one-page IP summary. Patents and status, license type, field, territory, milestones, university economics, government rights, inventors. That page should answer most early IP questions before anyone asks them.

Ask the tech transfer office for the compliance record. Invention disclosure dates, title election, any manufacturing waivers. They should have it, and most are glad to share it with a licensee who asks.

If the license isn't signed yet, negotiate with the exit in mind. Field breadth, assignability, milestone realism, and anti-dilution terms are far easier to shape now than after your first priced round, when everyone at the table has a stake in the current terms.

Put the answer in your deck — briefly. One line on the main slide ("exclusive worldwide license to two issued patents and one pending application") and the one-page summary in your appendix. When the question comes, you answer it in thirty seconds and move on.

That's the real goal. Not to have a perfect license — very few do — but to be the founder who answers the ownership question with specifics. The specifics are what keep the meeting moving toward diligence.

---

This post is a framework for preparing for investor questions, not legal advice. License terms, Bayh-Dole obligations, and federal funding conditions have real legal consequences, and your counsel should review the actual agreements before you rely on any of them.

---

A VentureReady evaluation reviews how your deck presents IP and the other questions investors ask spinouts, so the question from the end of the table gets a thirty-second answer. We review the deck, not the license agreement — that one belongs with your counsel. Slide by slide, in 24 hours. Upload your deck at VentureReady.ai.